Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer

被引：1

作者：

Parikh, Mamta

Pan, Chong-xian

Beckett, Laurel

Li, Yueju

Robles, Daniel

DeVisser, Christina

Lara, Primo

机构：

[1] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA

[2] UC Davis Hlth, Comprehens Canc Ctr, Sacramento, CA USA

[3] Univ Calif Davis, Sacramento, CA 95817 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.4541

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4541

引用

页数：1

共 50 条

[41] Gemcitabine and Docetaxel in Metastatic, Castrate-Resistant Prostate Cancer Results From a Phase 2 Trial
Garcia, Jorge A.
Hutson, Thomas E.
Shepard, Dale
Elson, Paul
Dreicer, Robert
CANCER, 2011, 117 (04) : 752 - 757
[42] Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.
Hassel, Jessica Cecile
Berking, Carola
Schlaak, Max
Eigentler, Thomas
Gutzmer, Ralf
Ascierto, Paolo Antonio
Schilling, Bastian
Hamm, Svetlana
Hermann, Frank
Reimann, Philip Gero
Schadendorf, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43] A phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer
Ignatiadis, M.
Polyzos, A.
Stathopoulos, G. P.
Tselepatiotis, E.
Christophyllakis, Ch.
Argyraki, K.
Androulakis, N.
Vardakis, N.
ANNALS OF ONCOLOGY, 2006, 17 : 311 - 311
[44] Pembrolizumab Versus Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer
Takemura, Ayana
Matsushita, Yuto
Tamura, Keita
Sugiyama, Takayuki
Nagata, Masao
Otsuka, Atsushi
Miyake, Hideaki
IN VIVO, 2021, 35 (03): : 1889 - 1894
[45] Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC)
Zhang, Tian
Staats, Janet S.
Chan, Cliburn
Harrison, Michael Roger
O'Donnell, Peter H.
Batich, Kristen A.
Chen, Tianling
Krejsa, Cecile
Izumi, Raquel
George, Daniel J.
Weinhold, Kent J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[46] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
Possinger, K
Kaufmann, M
Coleman, R
Stuart, NSA
Helsing, M
Ohnmacht, U
Arning, M
ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
[47] Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas - Results of a phase II trial
Dileo, Palma
Morgan, Jeffrey A.
Zahrieh, David
Desai, Jayesh
Salesi, Jeanine M.
Harrnon, David C.
Quigley, M. Travis
Polson, Kathleen
Demetri, George D.
George, Suzanne
CANCER, 2007, 109 (09) : 1863 - 1869
[48] A PHASE IB TRIAL OF RAMUCIRUMAB (RAM), IN COMBINATION WITH DOCETAXEL (D) IN JAPANESE PATIENTS WITH ADVANCED METASTATIC BREAST CANCER (MBC)
Iwata, H.
Masuda, N.
Aogi, K.
Xu, Y.
Ibrahim, A.
Sasaki, Y.
ANNALS OF ONCOLOGY, 2013, 24 : 38 - 38
[49] Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: A phase II trial of sequential chemotherapy
Dols M.C.
Chamorro E.V.
Díaz I.A.
Calle S.G.
García J.A.
Calderón V.G.
Ocón F.C.
Pino Á.M.
Bretón García J.J.
Orgaz M.B.
Clinical and Translational Oncology, 2006, 8 (10) : 742 - 749
[50] A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer
Martina Baur
Allan T. van Oosterom
Véronique Diéras
Michele Tubiana-Hulin
R. Charles Coombes
Thomas Hatschek
Michael Murawsky
May Klink-Alakl
Marcus Hudec
Christian Dittrich
Journal of Cancer Research and Clinical Oncology, 2008, 134 : 125 - 135

← 1 2 3 4 5 →